| Literature DB >> 26600629 |
Raimundo Castro1, Hernando Samuel Pinzón2, Nelson Alvis-Guzman3.
Abstract
OBJECTIVE: Our objective was to systematically review the published observational research related to the role of oxidative-nitrosative stress in pathogenesis of dengue.Entities:
Keywords: Dengue; biological markers; dengue virus; nitrosative stress; oxidative stress; severe dengue; systematic review
Mesh:
Substances:
Year: 2015 PMID: 26600629 PMCID: PMC4640436
Source DB: PubMed Journal: Colomb Med (Cali) ISSN: 0120-8322
Figure 1. Flow diagram of studies included in the systematic review.
Observational evidences of oxidative and nitrosative stress involvement in dengue pathogenesis
| Study: author, Country, Reference | Study Design | Original purposes | Sample size | Outcomes |
|---|---|---|---|---|
| Ray, India, 50 | Case-control | To evaluate the status of antioxidants, enzymes of hepatic and muscular origin and other biochemical indicators in children with dengue illness at admission | 66 children with dengue | SOD: ↑Patients vs. Controls ( |
| (45 days to 12 yrs ) | ||||
| 25 healthy children | GPx: ↓ Patients vs. Controls ( | |||
| Follow-up period: none | ||||
| Valero, Venezuela, 34 | Case-control | To determine the serum concentration of NO in patients with DF and DHF | 105 patients with dengue | Nitric oxide: |
| 53 healthy individuals | ↑ DF vs. DHF (p <0.01) | |||
| (Age-matched controls) | ↑ DF vs. Controls (p <0.01) | |||
| Follow-up period: none | ||||
| Gil, Cuba, 39 | Case-control | To study the status of some oxidative stress markers in serologically confirmed adults dengue patients comparing with those observed in healthy individuals | 22 adults with dengue | TAS (day 7): ↑ Patients vs. Controls ( |
| (21 to 58 yrs) | ||||
| 22 healthy individuals | PP - SOD - MDA/4-HAD (days 3-5-7): ↑ Patients vs. Controls ( | |||
| (Sex- and age-matched controls) | ||||
| Follow-up period: 7 days | THs - GPx (days 3-5-7): ↓ Patients vs. Controls ( | |||
| Klassen, Guatemala, 40 | Case-control | To report data of several micronutrients with antioxidants in patients with classic dengue fever during the acute phase and convalescence from the disease and from appropriate reference control subjects | 9 adults with dengue | Retinol: ↓ Patients (DI+DII) vs. Controls ( |
| (18 to 68 yrs) | Retinol (patients): ↓ DI vs. DIII ( | |||
| 12 healthy individuals | b-carotene: ↓ DII vs. DIII (p= 0.03) | |||
| Follow-up period: | GSH: ↓ DII vs. DI ( | |||
| DI: admission to the hospital | GSH (at DIII): ↓ Patients vs. Controls ( | |||
| DII: 5 days after admission (discharge) | TBARS (DI+DII): ↑ Patients vs. Controls ( | |||
| DIII: 7 days after admission | TBARS (at DIII): ↑ Patients vs. Controls ( | |||
| TAS (DI vs. DII): ↓ Patients vs. Controls (p= 0.01) | ||||
| Trairatvorakul, Thailand, 35 | Case-control | To correlate nitric oxide levels in three groups with different severity ranging from DF, DHF I/II, to DSS, and to compare the results with a control group | 110 children with dengue | Nitric oxide: |
| (<15 yrs) | ↓ Patients vs. Controls (p <0.05) | |||
| 38 healthy children | ↑DF vs. DHF I/II (p <0.05) | |||
| (Age-matched controls) | ↓ DHF I/II vs. DSS (p <0.05) | |||
| Follow-up period: none | ||||
| Rojas, Colombia, 51 | Cross-sectional study | To evaluate the association between the levels of glutathione peroxidase and the manifestations and complications of dengue | 161 patients with dengue | GPx: |
| (6 to 85 yrs) | ↑ Patients with hemorrhages vs Patients without hemorrhages (p= 0.03) | |||
| Chareonsirisuthigul, Thailand, 25 | Cross-sectional study | To investigate the effect of antibody-dependent enhancement infection on pro- and anti-inflammatory cytokines production | 60 children with dengue | Nitric oxide (secondary DHF): |
| (5 to 10 yrs) | ↓ Fever day vs. Convalescent day (p <0.05) | |||
| Soundravally, India, 48 | Case-control | To assess whether oxidative stress induced changes in plasma protein can be an early predictor of severe dengue disease | 80 patients with dengue (26-53 yrs) | PCO: |
| ↑ Patients vs. Controls (p <0.001) | ||||
| 63 healthy individuals | ↓ DF vs. DHF (p <0.05) | |||
| ↓ DF vs. DSS (p <0.05) | ||||
| ↓ DHF vs. DSS (p <0.05) | ||||
| (Sex- and age-matched controls) | PBSH: | |||
| ↓ Patients vs. Controls (p <0.001) | ||||
| Follow-up period: none | ↑ DF vs. DHF (p <0.05) | |||
| ↑ DF vs. DSS (p <0.05) | ||||
| Soundravally, India, 41 | Case-control | To investigate the association of lipid peroxidation and protein carbonylation with thrombocytopenia in the different clinical spectrum of dengue infection | 80 patients with dengue (26-53 yrs) | MDA (3-5-7 days): |
| ↑ Patients vs. Controls (p <0.05) | ||||
| 63 healthy individuals | ↓ DF vs. DSS (p <0.05) | |||
| MDA (5-7 days): | ||||
| (Sex- and age-matched controls) | ↓ DF vs. DHF (p <0.05) | |||
| PCOs (7 day): | ||||
| Follow-up period: | ↑ Patients vs. Controls (p <0.001) | |||
| TAS (3-5-7 days): | ||||
| 7 days | ↓ DSS vs. Controls (p <0.05) | |||
| Mendes-Ribeiro, Brazil, 36 | Case-control | To investigate the effects of DF on the platelet L-arginine-NO pathway, platelet function and an inflammatory acute-phase protein fibrinogen | 16 patients with DF | Total rates of L-arginine transport and L-arginine transport via system y+L: |
| (35 ± 4 yrs) | ↑ DF vs. Controls (p <0.05) | |||
| 18 healthy controls | Total NOS activity: | |||
| (Age-matched controls) | ↑ DF vs. Controls (p <0.05) | |||
| Follow-up period: none | ||||
| Seet, Singapore, 45 | Case-control | To investigate oxidative stress during dengue infection | 28 patients with dengue | Plasma HETEs: |
| (23-68 yrs) | ↑ Febrile stage vs. Controls (p <0.05) | |||
| ↑ Febrile stage vs. Convalescent stage (p <0.05) | ||||
| 28 healthy controls | COPs: | |||
| ↓ Febrile stage vs. Controls (p <0.05) | ||||
| (Age-matched controls) | Urinary F2-IsoPs: | |||
| ↑ Febrile stage vs. Controls (p <0.05) | ||||
| Follow-up period: 25 days | ↑ Febrile stage vs. Convalescent stage (p <0.05) | |||
| Lee, Singapore, 46 | Case-control | To provide further insight into the relation between lipid oxidation products and human diseases | 35 patients with dengue (25-86 yrs) | Plasma free F2-IsoPs: |
| ↑ DF onset vs. Controls (p <0.01) | ||||
| ↑ DF onset vs. DF recovery (p <0.01) | ||||
| 47 healthy controls | Urinary F2-IsoPs: | |||
| ↑ DF onset vs. Controls (p <0.01) | ||||
| ↑ DF onset vs. DF recovery (p <0.01) | ||||
| (Age-matched controls) | Plasma total HETEs: | |||
| ↑ DF onset vs. Controls (p <0.01) | ||||
| ↑ DF onset vs. DF recovery (p <0.01) | ||||
| Follow-up period: none | COPs: | |||
| ↓ DF onset vs. Controls (p <0.05) | ||||
| ↓ DF onset vs. DF recovery (p <0.05) | ||||
| Levy, Venezuela, 28 | Cross-sectional study | To compare the serum levels of IL-6, TNFa, IL-1b, NO, CRP, C3 and apoptosis in DENV-infected patients and in monocytes/macrophages cultures | 36 patients with DF | Nitric oxide: |
| ↑ DF vs. Controls (p <0.001) | ||||
| (3-53 yrs) | ↑ DF vs. DHF (p <0.001) | |||
| ↑ Primary infection vs. Controls (p <0.001) | ||||
| 34 patients with DHF | ↑ Secondary infection vs. Controls (p <0.001) | |||
| (3-53 yrs) | ↓ Primary infection vs. Secondary infection (p <0.001) | |||
| Matsuura, Brazil, 37 | Case-control | To investigate L-arginine transport as well as activity and expression of iNOS in DHF platelets | 23 patients with DHF (33±14 yrs) | L-arginine transport via system y+L: |
| 25 healthy individuals | ↑ DHF vs. Controls (p <0.05) | |||
| (Age-matched controls) | Total NOS activity: | |||
| Follow-up period: none | ↑ DHF vs. Controls (p <0.05) | |||
| Gil, Cuba, 44 | Case-control | To study the status of an extensive array of redox indexes as proposal of an integral and dynamic characterization of redox status | 22 patients with dengue | MDA - HPO - SOD - PP: ↑ Patients vs. Controls ( |
| (18-84 yrs) | ||||
| 194 healthy individuals | GSH: | |||
| (Age-matched controls) | ↓ Patients vs. Controls (p <0.05) | |||
| Follow-up period: 7 days | ||||
| Soundravally, India, 13 | Case-control | To evaluate the levels of plasma MDA, TNF-a and IFN-g during defervescence, in all the three clinical groups of dengue compared to uninfected blood samples | 81 patients with dengue | MDA: |
| (16-67 yrs) | ↓ DF vs. DHF (p <0.001) | |||
| 30 healthy individuals | ↓ DF vs. DSS (p <0.001) | |||
| (Sex- and age-matched controls) | ↓ DHF vs. DSS (p= 0.017) | |||
| Follow-up period: none |
DF: dengue fever; DHF: dengue hemorrhagic fever; SOD: superoxide dismutase; GSH: glutathione; GPX: glutathione peroxidase; ALB: albumin; CAT: catalase; MDA: malondialdehyde; PCO: protein carbonyl; HETEs: hydroxyl-eicosatetraenoic acid; COPs: cholesterol oxidative products; F2-ISOPs: F2-isoprostanes; TAS: total antioxidants status; HPO: hydroperoxides; PP: peroxidation potential; THs: total hydroperoxides.
Comparison of methods used and values reported in reviewed studies.
| Markers | Methods | Reported values | References |
|---|---|---|---|
| NO | Spectrophotometric detection | ||
| Absorbance at 540 nm. (Griess reagent) | DF cases (DENV-1): 57.4 ± 3.02 mM | 34 | |
| DF cases (DENV-4): 55.6 ± 2.25 mM | |||
| DHF cases (DENV-2): 13.87 ± 2.05 mM | |||
| DHF cases (DENV 4): 14.33 ± 1.25 mM | |||
| Controls: approx. 25 mM | |||
| Absorbance at 540 nm. (Commercial kit, Griess method) | DF cases: approx. 40 mM | 28 | |
| DHF cases: approx. 22 mM | |||
| Controls: approx. <10 mM | |||
| DF cases: 124.94 ± 36.79 mM | 35 | ||
| DHF I/II cases: 99.69 ± 33.42 mM | |||
| DHF III/IV cases: 120.63 ± 46.26 mM | |||
| Controls: 168.18 ± 24.10 mM | |||
| MDA | Absorbance at 532 nm. (Satoh method) | Dengue cases: 4.9 ± 0.9 mM | 13 |
| Controls: 1.9 ± 0.4 mM | |||
| Absorbance at 586 nm. MDA + 4-HDA. (Commercial kit) | Dengue cases: approx. 10-18 mM | 39 | |
| Controls: approx. <10 mM | |||
| Difference in absorbances at 532 and 572 nm. (Jentzsch method) | Dengue cases: 0.624 ± 0.144 mM | 40 | |
| Controls: 0.450 ± 0.116 mM | |||
| Absorbance at 532 nm. (Satoh method) | Dengue cases: approx. 2-8 mM | 41 | |
| Controls: approx. 2 mM | |||
| THS | Absorbance at 560 nm. Oxidation of Fe(II) to Fe (III) by THs. (Commercial kit) | Dengue cases: approx. 50-150 mM | 39 |
| Controls: approx. 200-280 mM | |||
| Absorbance at 560 nm. Oxidation of Fe(II) to Fe (III) by THs | Dengue cases: 119.6 ± 34.61 mM | 44 | |
| Controls: 70.3 ± 13.9 mM | |||
| PCOs | Absorbance at 366 nm. (Method of Levine) | Dengue cases: approx. 3.0-8.0 nmol/mg protein | 41 |
| Controls: approx. 2.0-2.5 nmol/mg protein | |||
| DF cases: 4.98 ± 0.47 nmol/mg protein | 48 | ||
| DHF cases: 5.95 ± 0.61 nmol/mg protein | |||
| DSS cases: 6.66 ± 0.70 nmol/mg protein | |||
| Controls: 1.97 ± 0.56 nmol/mg protein | |||
| SOD | Absorbance at 505 nm. (commercial kit) | DENV cases: approx. 1.8-3.0 U/ml | 39 |
| Controls: approx. 1.2-1.7 U/ml | |||
| DENV cases: 2.26 ± 0.71 U/mg Hb | 44 | ||
| Controls: 1.41 ± 0.72 U/mg Hb | |||
| Absorbance at 480 nm. (Epinephrine method) | DF: 26.85 ± 8.13 U/ml | 50 | |
| DHF: 23.17 ± 9.98 U/ml | |||
| DSS: 24.86 ± 9.22 U/ml | |||
| Controls: 2.31 ± 0.97 U/ml |
NO: Nitric oxide; MDA: Malondialdehyde; 4-HAD: 4-hydroxyalquenals; TBARS: Thiobarbituric acid reactive substances; THs: Total hydroperoxides; PCOs: protein carbonyls; SOD: Superoxide dismutase; DF: dengue fever; DHF: dengue hemorrhagic fever; DSS: dengue syndrome shock; UV: ultraviolet.